CN102397546A - Medicine administration method for olfactorily or gustatorily sensitive animals - Google Patents
Medicine administration method for olfactorily or gustatorily sensitive animals Download PDFInfo
- Publication number
- CN102397546A CN102397546A CN2010102814383A CN201010281438A CN102397546A CN 102397546 A CN102397546 A CN 102397546A CN 2010102814383 A CN2010102814383 A CN 2010102814383A CN 201010281438 A CN201010281438 A CN 201010281438A CN 102397546 A CN102397546 A CN 102397546A
- Authority
- CN
- China
- Prior art keywords
- administration
- medicine
- drinking
- water
- taste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a medicine administration method for olfactorily or gustatorily sensitive animals. According to the invention, the administration method is drinking administration. The medicine is a composite preparation of a quinolinone medicine and a smell covering agent. Olfactorily or gustatorily sensitive animals are likely to refuse to take medicines when they smell medicines with unpleasant smells. The medicine administration method provided by the invention is mainly aimed at solving the problem. Also, traditional injection administration or mixed-feeding administration methods cause problems of high administration labor intensity, severe animal stress reactions, and influenced medicine intake due to reduced feed intake of sick animals. With the method provided by the invention, the problems can be solved. With the administration method provided by the invention, disease-treating characteristics of the medicine can be developed, and animals can take the medicine through daily drinking. Therefore, the method is convenient and fast, and provides a good administration effect.
Description
Technical field
The present invention relates to the administration field in the Animal diseases treatment, be specifically related to a kind of drug administration method that is used for olfactory sensation or sense of taste responsive type animal.
Background technology
In Animal diseases medication therapeutic process; Some medicines are arranged because its bitter in the mouth or taste are unhappy, make the responsive animal of the olfactory sensation or the sense of taste produce the reaction that refusal is taken medicine easily, therefore can not directly throw clinically to; Processing certain dosage form can use, and for example processes injection, capsule etc.Injection is used for directly injecting to animal, but in the actual therapeutic process, it is individual that drug administration by injection is primarily aimed at morbidity, if then there are problems such as labor intensity is big, the animal stress is big in colony's administration.Capsule is mainly raised administration through mixing, but the feed intake of animal after sick descend, and has influenced the intake of food, thereby has also influenced the action effect of medicine.Because the principle of capsule is to be wrapped in wherein with the pharmaceutical pack that capsule will have a unhappy abnormal smells from the patient, and unhappy odor dispersion is not come out, can not be smelt or when edible, feel by animal; But this capsule is met after the water, and capsule-wall can be melted, and causes the drug exposure of the inside to be come out, and unhappy abnormal smells from the patient also distributes thereupon, and animal also can refuse to take.Therefore, press for a kind of pharmaceutical preparation at present and can give animal-use drug through the method for drinking-water administration.Another advantage of drinking-water administration is that though the appetite of animal after sick descends, amount of drinking water can not receive sick influence, and the administration of therefore drinking water can make animal better take in medicine, and is more efficient and convenient to treatment of diseases.
Summary of the invention
The objective of the invention is to cover the problem that medicine goes out to distribute unhappy abnormal smells from the patient fully, a kind of medication that can make the normal medication of animal is provided according to what exist in the existing medication.
The object of the invention is achieved through following technical scheme:
A kind of drug administration method that is used for olfactory sensation or sense of taste responsive type animal, this method is the drinking-water administration, said medicine is the compound formulation of QNS and odor mask.
Further, said compound formulation is made up of following components in percentage by mass: QNS or its esters chemical compound 0.5～95%, organic acid or its esters chemical compound 0.1～97%; Sweeting agent 0.1～98.5%; Flavour enhancer 0～45%, flavouring agent 0～10%, surplus is an excipient.
The present invention is used for the drug administration method of olfactory sensation or sense of taste responsive type animal, and said olfactory sensation or sense of taste responsive type animal most preferably are pig, Canis familiaris L., cattle, goat or rabbit.Known pig is olfactory sensation and the sense of taste one of the most sensitive animal in numerous animals, and with the physiognomy ratio, the taste bud number of pig is more, is respectively bacterium shape (5000 of pigs; Human 1600), cup-shaped (pig＞10000, human 6000) and lobate (4800 of pigs; Human 3000) (Hellekant and Danilova, 1999), generally; The taste bud number of pig is 3～4 times of people, and therefore in medication, pig is the most responsive to the abnormal smells from the patient or the taste of medicine; The olfactory sensation of Canis familiaris L. is responsive, and its sensitivity approximately is 100 times of people, but its sense of taste is more insensitive.The taste bud number statistics of common animals is as shown in table 1:
The taste bud number of table 1 different animals is estimated
*Chamorro?et?al.1993。
When the compound formulation that uses medication of the present invention to take to pig, the addition of said compound formulation in the daily drinking-water of pig counted 0.01～0.15g/L with the quinolones principal agent.
Compared with prior art, the present invention has following beneficial effect:
The drug administration method that the present invention is used for olfactory sensation or sense of taste responsive type animal has overcome can produce the difficulty that refusal is taken medicine to olfactory sensation or sense of taste responsive type animal when smelling the medicine with unhappy abnormal smells from the patient, also solved traditional drug administration by injection or mixed to raise that colony's administration labor intensity that administration causes is big, big, the sick animal feed intake of animal stress descends problems such as influencing the medicine intake.Medication of the present invention can make animal only can take in medicine through daily drinking-water in the characteristics of performance Drug therapy disease, and is convenient and swift, effective.
The specific embodiment
Come further to explain the present invention below in conjunction with embodiment, but embodiment does not do any qualification to the present invention.
Embodiment 1
Enrofloxacin 359g is placed the there-necked flask of 5L, add among the absolute methanol 1000ml, start stirring.Other is dissolved in the 118g succinic acid in the 600ml absolute methanol, it is dropped in the above-mentioned flask, and reflux 4 hours, pick test, behind the judgement reaction end, stopped reaction, filtration, absolute methanol washing, oven dry get 470g enrofloxacin succinate.
Embodiment 2
Levofloxacin 361g is placed the there-necked flask of 5L, add among the dehydrated alcohol 1200ml, start stirring.In addition the 192g citric acid is dissolved in the 750ml dehydrated alcohol, it is dropped in the above-mentioned flask, reflux 5 hours, pick test, behind the judgement reaction end, stopped reaction, filtration, absolute ethanol washing, oven dry get 543g levofloxacin citrate.
Embodiment 3
With the enrofloxacin succinate of embodiment 1 preparation and other components by following prescription through mixing, pulverize, sieving, well-established law prepares the enrofloxacin powder.
Enrofloxacin succinate 13.3%
Sucralose 5%
Ethyl vanillin 0.5%
Sodium chloride 30%
Anhydrous glucose adds to full dose 100%.
Embodiment 4
Enrofloxacin 0.5%
Succinic acid 95%
Sucralose 3%
Vanillin 0.1%
Sucrose adds to full dose 100%
Mix, pulverize, sieve, wet granulation, oven dry, well-established law makes granule.
Embodiment 5
Enrofloxacin 20%
Citric acid 15%
Alitame 3%
Ethyl vanillin 0.5
Sodium chloride 15%
Soluble starch adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 6
The enrofloxacin powder that makes by embodiment 3 methods is a binding agent with 5% alcoholic solution of PVP, wet granulation, and oven dry, well-established law makes granule.
Embodiment 7
Enrofloxacin 75%
Fumaric acid 12%
Alitame 10%
Dextrin adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 8
Enrofloxacin sodium salt 95%
Succinic acid sodium salt 1%
Sodium glutamate 3%
Neotame 0.1%
Lactose adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder, or well-established law is processed granule.
Embodiment 9
Ciprofloxacin hydrochloride 35%
Malic acid 10%
Acesulfame potassium 50%
Soluble starch adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 10
With the powder that embodiment 9 makes, be binding agent with the starch slurry, wet granulation, oven dry gets granule.
Embodiment 11
Norfloxacin nicotinate 14%
Citric acid 24%g
Sodium bicarbonate 30%
P-ethoxyphellylurea 10%
Dextrin 10%
Lactose adds to full dose 100%
With the said components pulverize separately, sieve, dry, control moisture below 1%, with norfloxacin nicotinate, P-ethoxyphellylurea, dextrin and lactose mix homogeneously; Adding the aforementioned component mixing after sodium bicarbonate, citric acid being granulated respectively, is binding agent with the PVP ethanol solution again, and well-established law is granulated, and gets effervescent granule.
Embodiment 12
Pressing prescription and the method for preparing of embodiment 11, add an amount of PEG6000 again as releasing agent, is binding agent with PVP, and the well-established law tabletting makes the norfloxacin effervescent tablet.
Embodiment 13
Levofloxacin citrate 0.5%
Acesulfame potassium 98.5%
Glucose adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 14
Sarafloxacin hydrochlorate 11%
Salicylic acid 40%
Sucralose 20%
Cream flavour 0.5%
Sodium glutamate 12.5%
Lactose adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 15
Enrofloxacin 2.5%
Succinic acid 45%
Alitame 8%
EDTA 0.05％
Sodium chloride 10%
Mandarin orange essence 1%
Purified water adds to full dose 100%w/vw
Enrofloxacin is placed 1/2 of full dose purified water, add the succinic acid stirring and dissolving, again all the other components are added stirring and dissolving, add the residue purified water, standardize solution filters with 0.45 micron membranes, fill, and sterilization makes solution.
Embodiment 16
Difloxacin 20%
Tartaric acid 44%
Alitame 12%
Chocolate essence 0.5%
Sodium chloride 22%
Glucose adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 17
Enrofloxacin sodium salt 10.7%
Potassium citrate 12.5%
Glucide 40%
Sodium glutamate 20%
Cream flavour 0.8%
Glucose adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 18
Danofloxacin mesylate 25.4%
Fumaric acid 8%
Sucralose 9.5%
Mandarin orange essence 1%
Lactose adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 19
Pefloxacin mesylate 12.9%
Salicylic acid 5%
Alitame 5%
Cream flavour 1%
Dextrin adds to full dose 100%
Mix, pulverize, sieve, well-established law makes powder.
Embodiment 20
Marbofloxacin 20%
Fumaric acid 10%
Succinic acid 8%
Alitame 15%
Vanillin 0.1%
Glucose adds to full dose 100%
Mix, pulverize, sieve, conventional method makes powder.
Embodiment 21
Lomefloxacin hydrochloride 35%
Salicylic acid 5%
Tartaric acid 10%
To oxygen ethyl phenylurea 20%
Chocolate essence 5%
Lactose adds to full dose 100%
Mix, pulverize, sieve, promptly get powder.
Embodiment 22
Orbifloxacin 15%
Succinic acid 25%
Tartaric acid 10%
Sucralose 20%
Cream flavour 0.5%
Sucrose adds to full dose 100%
Mix, pulverize, sieve, promptly get powder.
Embodiment 23
Healthy 96 of farrowing sows (conceived 9 weeks) are divided into 3 groups, administering mode at random: the drinking-water administration.If blank group: drink water for not adding the clear water of any material; The Enrofloxacin HCL group: adding Enrofloxacin HCL in the drinking-water, is 0.1g/L (100ppm) by enrofloxacin concentration; 3 groups of the embodiment of the invention: adding the powder that the embodiment of the invention 3 makes in the drinking-water, is 0.1g/L (100ppm) by enrofloxacin concentration.
Preliminary experiment 3 days (divide into groups but do not add medicine) writes down 3 groups amount of drinking water, basic identical zero difference.Added in the 4th day, observed 12 hours, record is respectively organized amount of drinking water such as table 1 and is shown:
Table 2
Embodiment 24
Healthy 96 of farrowing sows (conceived 11 weeks) are divided into 3 groups, administering mode at random: the drinking-water administration.If blank group: drink water for not adding the clear water of any material; The Enrofloxacin HCL group: adding Enrofloxacin HCL in the drinking-water, is 0.025g/L (25ppm) by enrofloxacin concentration; 15 groups of the embodiment of the invention: adding the solution that the embodiment of the invention 15 makes in the drinking-water, is 0.025g/L (25ppm) by enrofloxacin concentration.
Preliminary experiment 3 days (divide into groups but do not add medicine) writes down 3 groups amount of drinking water, basic identical zero difference.Added in the 4th day, observed 12 hours, record is respectively organized amount of drinking water such as table 2 and is shown:
Table 3
Embodiment 25
Healthy 48 of nursing sow (2 weeks of puerperal) are divided into 3 groups, administering mode at random: the drinking-water administration.If blank group: drink water for not adding the clear water of any material; Enrofloxacin sodium salt group: adding the enrofloxacin sodium salt in the drinking-water, is 0.1g/L (100ppm) by enrofloxacin concentration; 17 groups of the embodiment of the invention: adding the powder that the embodiment of the invention 17 makes in the drinking-water, is 0.1g/L (100ppm) by enrofloxacin concentration.
Preliminary experiment 3 days (divide into groups but do not add medicine) writes down 3 groups amount of drinking water, basic identical zero difference.Added in the 4th day, observed 12 hours, record is respectively organized amount of drinking water such as table 3 and is shown:
Table 4
Embodiment 26
Healthy 48 of breeding boar of Du Luoke (2 weeks of puerperal) are divided into 3 groups, administering mode at random: the drinking-water administration.If blank group: drink water for not adding the clear water of any material; The ciprofloxacin group: adding ciprofloxacin in the drinking-water, is 0.125g/L (125ppm) by ciprofloxacin concentration; 9 groups of the embodiment of the invention: adding the powder that the embodiment of the invention 9 makes in the drinking-water, is 0.125g/L (125ppm) by ciprofloxacin concentration.
Preliminary experiment 3 days (divide into groups but do not add medicine) writes down 3 groups amount of drinking water, basic identical zero difference.Added in the 4th day, observed 12 hours, record is respectively organized amount of drinking water such as table 4 and is shown:
Table 5
Embodiment 27
60 of the pigs of the generation bacterial diarrhea of average weight 22kg are divided into 3 groups, administering mode at random: the drinking-water administration.If blank group: drink water for not adding the clear water of any material; The pefloxacin mesilate group: adding pefloxacin mesilate in the drinking-water, is 0.10g/L (100ppm) by pefloxacin concentration; 19 groups of the embodiment of the invention: adding the powder that the embodiment of the invention 19 makes in the drinking-water, is 0.10g/L (100ppm) by pefloxacin concentration.
Observed 24 hours, record is respectively organized amount of drinking water and therapeutic effect such as table 5 and is shown:
Table 6
Embodiment 28
180 of healthy big pigs (average weight 85kg) are divided into 3 groups, administering mode at random: the drinking-water administration.If blank group: drink water for not adding the clear water of any material; The levofloxacin hydrochloride group: adding levofloxacin hydrochloride in the drinking-water, is 0.05g/L (50ppm) by levofloxacin concentration; 13 groups of the embodiment of the invention: adding the powder that the embodiment of the invention 13 makes in the drinking-water, is 0.05g/L (50ppm) by levofloxacin concentration.
Observed 24 hours, record is respectively organized amount of drinking water such as table 6 and is shown:
Table 7
Embodiment 29
60 of the pigs of the generation bacterial diarrhea of average weight 35kg are divided into 5 groups, administering mode at random: the drinking-water administration.If blank group: drink water for not adding the clear water of any material; The husky star group of Abbott 56619: adding Abbott 56619 in the drinking-water, is 0.025g/L (25ppm) by difloxacin concentration; 16 groups of the embodiment of the invention: adding the powder that the embodiment of the invention 16 makes in the drinking-water, is 0.025g/L (25ppm) by difloxacin concentration; The Enrofloxacin HCL group: adding Enrofloxacin HCL in the drinking-water, is 0.05g/L (50ppm) by enrofloxacin concentration; 4 groups of the embodiment of the invention: adding the granule that the embodiment of the invention 4 makes in the drinking-water, is 0.05g/L (50ppm) by enrofloxacin concentration
Observed 24 hours, record is respectively organized amount of drinking water and therapeutic effect such as table 8 and is shown:
Table 8
Embodiment 30
Suffer from 6 of the milch cows of acute mastitis, clinical symptoms: the palpation breast has slight heating, pain, swelling.Milk has floccule or grumeleuse, and milk is thinning, the pH value meta-alkalescence, and somatic cell counting and chloride content all increase, and are divided into 2 groups at random, administering mode: the drinking-water administration.If matched group: intramuscular injection, get commercially available ENNUOSHAXING ZHUSHEYE, by per kilogram of body weight 2.5mg (in enrofloxacin) intramuscular injection, every day 1 time, logotype 5 days; 4 groups of the embodiment of the invention: adding the granule that the embodiment of the invention 4 makes in the drinking-water, is 0.025g/L (25ppm) by enrofloxacin concentration.
Observed 5 days, record is respectively organized amount of drinking water and therapeutic effect such as table 10 and is shown:
Table 9
* annotate: clinical symptoms improvement rate is that each item clinical symptoms index is added and calculates and get.
Claims (4)
1. a drug administration method that is used for olfactory sensation or sense of taste responsive type animal is characterized in that this method is the drinking-water administration, and said medicine is the compound formulation of QNS and odor mask.
2. the drug administration method that is used for olfactory sensation or sense of taste responsive type animal according to claim 1; It is characterized in that said compound formulation is made up of following components in percentage by mass: QNS or its esters chemical compound 0.5～95%; Organic acid or its esters chemical compound 0.1～97%, sweeting agent 0.1～98.5%, flavour enhancer 0～45%; Flavouring agent 0～10%, surplus are excipient.
3. the drug administration method that is used for olfactory sensation or sense of taste responsive type animal according to claim 2 is characterized in that said olfactory sensation or sense of taste responsive type animal are pig, Canis familiaris L. or cattle.
4. the drug administration method that is used for olfactory sensation or sense of taste responsive type animal according to claim 3 is characterized in that the addition of said compound formulation in the daily drinking-water of pig count 0.01～0.15g/L with the quinolones principal agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102814383A CN102397546A (en) | 2010-09-10 | 2010-09-10 | Medicine administration method for olfactorily or gustatorily sensitive animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102814383A CN102397546A (en) | 2010-09-10 | 2010-09-10 | Medicine administration method for olfactorily or gustatorily sensitive animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102397546A true CN102397546A (en) | 2012-04-04 |
Family
ID=45880442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102814383A Pending CN102397546A (en) | 2010-09-10 | 2010-09-10 | Medicine administration method for olfactorily or gustatorily sensitive animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102397546A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737567A (en) * | 2022-10-19 | 2023-03-07 | 湖南中科汇智信息服务有限公司 | Enrofloxacin soluble powder capable of reducing bitter taste and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1518449A (en) * | 2001-06-20 | 2004-08-04 | ����˹�ж�-����˹˹������˾ | Pediatric formulation of gatifloxacin |
| CN1642415A (en) * | 2002-03-12 | 2005-07-20 | 布里斯托尔-迈尔斯斯奎布公司 | Palatable oral suspension and method |
-
2010
- 2010-09-10 CN CN2010102814383A patent/CN102397546A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1518449A (en) * | 2001-06-20 | 2004-08-04 | ����˹�ж�-����˹˹������˾ | Pediatric formulation of gatifloxacin |
| CN1642415A (en) * | 2002-03-12 | 2005-07-20 | 布里斯托尔-迈尔斯斯奎布公司 | Palatable oral suspension and method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737567A (en) * | 2022-10-19 | 2023-03-07 | 湖南中科汇智信息服务有限公司 | Enrofloxacin soluble powder capable of reducing bitter taste and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102397552B (en) | A kind of medicine compound preparation of quinolone containing class and its preparation method and application | |
| US20110014132A1 (en) | Solid effervescent mixture for the oral absorption | |
| Howard et al. | Drugs and breastfeeding | |
| CN102438596A (en) | Dosage form for insertion into the mouth | |
| WO2021030607A1 (en) | Pimavanserin for treating neurodegenerative diseases | |
| Singh et al. | An overview on fast disintegrating sublingual tablets | |
| CN101874882A (en) | Strong loquat leaf extract (blended with honey) and preparation method thereof | |
| US20070141169A1 (en) | Homeopathic drug composition and methods of use thereof | |
| CN105343056A (en) | Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application | |
| CN101912613B (en) | Taste masking preparation | |
| CN102397546A (en) | Medicine administration method for olfactorily or gustatorily sensitive animals | |
| CN101129188B (en) | Legalon mastication patch and method of preparing the same | |
| Lakshmi et al. | Formulation and evaluation of domperidone candy lozenges | |
| CN102697751A (en) | Enrofloxacin effervescent dispersible tablets special for animals and preparation method of same | |
| US20220062360A1 (en) | Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery | |
| WO2015042596A1 (en) | Treatment of atopic dermatitis in non-human animals | |
| WO2015059638A2 (en) | Cns stimulant and opioid receptor antagonist combination as a non- addictive, non-aversive and synergistic anti-obesity treatment | |
| CN101480397B (en) | Cefixime orally disintegrating tablet and preparation method thereof | |
| CN100509017C (en) | Medicine for treating biliary tract infection and prepn process thereof | |
| CN102861014A (en) | Worm-disease-resisting compound niclosamide tablet for beasts and birds and preparation method thereof | |
| CN103040835B (en) | A kind of Pharmaceutical composition containing sildenafil citrate and preparation method thereof | |
| CN106362159A (en) | Molecular skeleton type tilmicosin sustained release preparation and preparation method thereof | |
| US11324795B2 (en) | Composition comprising Hordeum vulgare extract for preventing or treating short stature | |
| Dwivedi et al. | CAFEEINE: AN IMPORTANT COMPONENT OF OUR DAILY METABOLISM | |
| JPH01243945A (en) | Smoking aversion gum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120404 |